Week In Review: China Life Science Venture Tie-Up: WuxiAnd Frontline Merge

Published: May 30, 2017

WuXi Healthcare Ventures and Frontline BioVentures will merge to form 6 Dimensions Capital, which will have nearly $800 million under management and plans to raise more; WuXi Biologics' upcoming Hong Kong IPO may bring in as much as $513 million; Shanghai's Zai Lab filed in the US to begin raising $150 million for its own venture fund; WuXi NextCODE is seeking an additional $200 million in venture capital; Symic Bio, a Bay-area matrix biology company, announced a $30 million B financing that includes two China investors; CANbridge Life Sciences of Beijing completed a $25 million Series B round for clinical trials; VoxelCloud, a Los Angeles-China medical artificial intelligence company, raised $10 million in a Series A round; Israel's EarlySense partnered with Shenzhen Lachesis mHealth to introduce its remote monitoring system in China; Janssen, a Johnson & Johnson research arm, plans to increase its investment in China to develop new drugs for lung disease, especially cancer; Celltrion of South Korea received approval to start China clinical trials of a Remicade biosimilar; Guangzhou Xiangxue was granted CFDA approval to begin clinical trials of a novel treatment for glioblastoma; and Xynomic Pharma, a US-China oncology startup, formed a partnership with the University of California San Francisco to conduct a Phase II/III clinical trial of its lead drug, which is designed to overcome chemotherapy resistance.

Back to news